Abstract
In chronic kidney disease patients on dialysis (CKD-G5D) accurate assessment of glycemic control is vital to improve their outcome and survival. The best glycemic marker for glucose control in these patients is still debated because several clinical and pharmacological factors may affect the ability of the available biomarkers to reflect the patient's glycemic status properly. This review discusses the role of glycated albumin (GA) both as a biomarker for glucose control and as a prognostic factor in CKD-G5D; it also looks at the pros and cons of GA in comparison to the other markers and its usefulness in hemodialysis and peritoneal dialysis.
| Original language | English |
|---|---|
| Pages (from-to) | 9-17 |
| Number of pages | 9 |
| Journal | Diabetes Research and Clinical Practice |
| Volume | 140 |
| DOIs | |
| Publication status | Published - Jun 1 2018 |
Fingerprint
Keywords
- Cardiovascular risk
- Diabetes
- Dialysis
- Glycated albumin
- Glycation
- Hemodialysis
- Mortality
- Peritoneal dialysis
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Endocrinology
Cite this
Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D). / Dozio, Elena; Corradi, Valentina; Proglio, Marta; Vianello, Elena; Menicanti, Lorenzo; Rigolini, Roberta; Caprara, Carlotta; de Cal, Massimo; Corsi Romanelli, Massimiliano M.; Ronco, Claudio.
In: Diabetes Research and Clinical Practice, Vol. 140, 01.06.2018, p. 9-17.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D)
AU - Dozio, Elena
AU - Corradi, Valentina
AU - Proglio, Marta
AU - Vianello, Elena
AU - Menicanti, Lorenzo
AU - Rigolini, Roberta
AU - Caprara, Carlotta
AU - de Cal, Massimo
AU - Corsi Romanelli, Massimiliano M.
AU - Ronco, Claudio
PY - 2018/6/1
Y1 - 2018/6/1
N2 - In chronic kidney disease patients on dialysis (CKD-G5D) accurate assessment of glycemic control is vital to improve their outcome and survival. The best glycemic marker for glucose control in these patients is still debated because several clinical and pharmacological factors may affect the ability of the available biomarkers to reflect the patient's glycemic status properly. This review discusses the role of glycated albumin (GA) both as a biomarker for glucose control and as a prognostic factor in CKD-G5D; it also looks at the pros and cons of GA in comparison to the other markers and its usefulness in hemodialysis and peritoneal dialysis.
AB - In chronic kidney disease patients on dialysis (CKD-G5D) accurate assessment of glycemic control is vital to improve their outcome and survival. The best glycemic marker for glucose control in these patients is still debated because several clinical and pharmacological factors may affect the ability of the available biomarkers to reflect the patient's glycemic status properly. This review discusses the role of glycated albumin (GA) both as a biomarker for glucose control and as a prognostic factor in CKD-G5D; it also looks at the pros and cons of GA in comparison to the other markers and its usefulness in hemodialysis and peritoneal dialysis.
KW - Cardiovascular risk
KW - Diabetes
KW - Dialysis
KW - Glycated albumin
KW - Glycation
KW - Hemodialysis
KW - Mortality
KW - Peritoneal dialysis
UR - http://www.scopus.com/inward/record.url?scp=85050301841&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050301841&partnerID=8YFLogxK
U2 - 10.1016/j.diabres.2018.03.017
DO - 10.1016/j.diabres.2018.03.017
M3 - Review article
C2 - 29596954
AN - SCOPUS:85050301841
VL - 140
SP - 9
EP - 17
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
SN - 0168-8227
ER -